HomeAI · summaries
Storia in 4 fonti
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
The deaths of three study participants led Novartis to halt development of rap-cel in multiple indications, while “transient” side effects pushed Bristol Myers to voluntarily…
- ·
endpoints.news
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
